(Total Views: 512)
Posted On: 05/07/2025 9:00:09 PM
Post# of 154604
Wow this really puts things in prepective. No wonder everyone is so focused on the 5 survivors.
When you step back and look at the survival tail, especially in a group where most patients had failed four prior lines of therapy, it’s striking
Key differences:
• ASCENT Trial (Trodelvy):
• Total patients: Over 500 randomized, with around 235 in the treatment arm.
• Survival outcomes:
• Median OS ~11.8 months
• 2-year survival: ~20%
• Only 2 patients survived beyond 30 months, which is <1%
• Leronlimab pooled analysis:
• Only 28 patients total
• 2-year survival: 24.8%
• 3-year: 19.8%
• 4+ years: 14.2% (4/28 patients) or 5
• All 4 long-term survivors were NED (no evidence of disease)
Ultra-refractory mTNBC patients are expected to have rapid decline, with few, if any, durable survivors. I guess I’m just realizing this after ohm comment.
That doesn’t happen by chance, especially after 4 prior lines of therapy.
When you step back and look at the survival tail, especially in a group where most patients had failed four prior lines of therapy, it’s striking
Key differences:
• ASCENT Trial (Trodelvy):
• Total patients: Over 500 randomized, with around 235 in the treatment arm.
• Survival outcomes:
• Median OS ~11.8 months
• 2-year survival: ~20%
• Only 2 patients survived beyond 30 months, which is <1%
• Leronlimab pooled analysis:
• Only 28 patients total
• 2-year survival: 24.8%
• 3-year: 19.8%
• 4+ years: 14.2% (4/28 patients) or 5
• All 4 long-term survivors were NED (no evidence of disease)
Ultra-refractory mTNBC patients are expected to have rapid decline, with few, if any, durable survivors. I guess I’m just realizing this after ohm comment.
That doesn’t happen by chance, especially after 4 prior lines of therapy.
(17)
(0)
